Pharmacokinetic evaluation of axitinib

Bibliography

• Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011-27
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGFR and its receptors. Nat Med 2003;9:669-76
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42
   PubMed Web of Science ®Google Scholar
• Mendel DB, Laird AD, Xin X, In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors. Clin Cancer Res 2003;9:327-37
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L, BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-109
   PubMed Web of Science ®Google Scholar
• Hu-Lowe DD, Zou HY, Grazzini ML, Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 2008;14:7272-83.
   PubMed Web of Science ®Google Scholar
• Rugo HS, Herbst RS, Liu G, Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005;23:5474-83.
   PubMed Web of Science ®Google Scholar
• Pithavala YK, Tortorici M, Toh M, Effect of rifampin on the pharmacokinetics of Axitinib (AG-013736) in Japanese and Caucasian healthy volunteers. Cancer Chemother Pharmacol 2010;65:563-70
   PubMed Web of Science ®Google Scholar
• Poller B, Iusuf D, Sparidans RW, Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics. Drug Metab Dispos 2011;39:729-35
   PubMed Web of Science ®Google Scholar
• Mignogna C, Staibano S, Altieri V, Prognostic significance of multidrug-resistance protein (MDR-1) in renal clear cell carcinomas: a five year follow-up analysis. BMC Cancer 2006;6:293
   PubMed Web of Science ®Google Scholar
• Pithavala YK, Tong W, Mount J, Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers. Invest New Drugs 2010:1-9
   Google Scholar
• Hoskins JM, Goldberg RM, Qu P, UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst 2007;99:1290-5
   PubMed Web of Science ®Google Scholar
• Tortorici M, Chen Y, Hee B, Effect of food on the pharmacokinetics (PK) of axitinib in healthy volunteers (HVs). Ejc Suppl 2010;8(5):71-1 Meeting Abstract: 273
   Web of Science ®Google Scholar
• Rixe O, Bukowski RM, Michaelson MD, Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 2007;8:975-84
   PubMed Web of Science ®Google Scholar
• Rini BI, Wilding G, Hudes G, Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J Clin Oncol 2009;27:4462-8
   PubMed Web of Science ®Google Scholar
• Rini BI, Escudier B, Tomczak P, Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011
   Web of Science ®Google Scholar
• Cohen EE, Rosen LS, Vokes EE, Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008;26:4708-13
   PubMed Web of Science ®Google Scholar
• Schiller JH, Larson T, Ou SH, Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. J Clin Oncol 2009;27:3836-41
   PubMed Web of Science ®Google Scholar
• Rini BI, Schiller JH, Fruehauf JP, Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors. Clin Cancer Res 2011;17:3841-9
   PubMed Web of Science ®Google Scholar
• Fruehauf J, Lutzky J, McDermott D, Multicenter, phase ii study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, in patients with metastatic melanoma. Clin Cancer Res 2011;17:7462-9
   PubMed Web of Science ®Google Scholar
• Spano JP, Chodkiewicz C, Maurel J, Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet 2008;371:2101-8
   PubMed Web of Science ®Google Scholar
• Kindler HL, Ioka T, Richel DJ, Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol 2011;12:256-62
   PubMed Web of Science ®Google Scholar
• Rugo HS, Stopeck AT, Joy AA, Randomized, placebo-controlled, double-blind, phase ii study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. J Clin Oncol 2011;29:2459-65
   PubMed Web of Science ®Google Scholar
• Bendell JC, Tournigand C, Bednarczyk M, Axitinib or bevacizumab (bev) plus FOLFOX or FOLFIRI as second-line therapy in patients (pts) with metastatic colorectal cancer (mCRC) [abstracts 29]. ASCO Meeting; 2011. p. 478
   Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Tomczak P, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24
   PubMed Web of Science ®Google Scholar
• Rixe O, Billemont B, Izzedine H. Hypertension as a predictive factor of Sunitinib activity. Ann Oncol 2007;18:1117
   PubMed Web of Science ®Google Scholar
• Rixe O, Dutcher JP, Motzer RJ, Association between diastolic blood pressure (Dbp) >= 90 Mmhg and efficacy in patients (Pts) with metastatic renal cell carcinoma (Mrcc) receiving axitinib (Ag-013736; Ag). Ann Oncol 2008;19:189-9
   Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment Of Cancer, National Cancer Institute Of The United states, National Cancer Institute Of Canada. J Natl Cancer Inst 2000;92:205-16
   PubMed Web of Science ®Google Scholar
• Yuh WT. An exciting and challenging role for the advanced contrast MR imaging. J Magn Reson Imaging 1999;10:221-2
   PubMed Web of Science ®Google Scholar
• Taylor JS, Tofts PS, Port R, MR imaging of tumor microcirculation: promise for the new millennium. J Magn Reson Imaging 1999;10:903-7
   PubMed Web of Science ®Google Scholar
• Padhani AR. Dynamic contrast-enhanced MRI in clinical oncology: current status and future directions. J Magn Reson Imaging 2002;16:407-22
   PubMed Web of Science ®Google Scholar
• Checkley D, Tessier JJ, Kendrew J, Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGFR signalling inhibitor, in PC-3 prostate tumours. Br J Cancer 2003;89:1889-95
   PubMed Web of Science ®Google Scholar
• Mukohara T, Nakajima H, Mukai H, Effect of axitinib (AG 013736) on fatigue, thyroid stimulating hormone, and biomarkers: a phase I study in Japanese patients. Cancer Sci 2010;101:963-8
   PubMed Web of Science ®Google Scholar
• Desai J, Yassa L, Marqusee E, Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 2006;145:660-4
   PubMed Web of Science ®Google Scholar
• Hoh C, Infante JR, Burris HA, Axitinib inhibition of [18F] fluorothymidine (FLT) uptake in patients (pts) with colorectal cancer (CRC): Implications for cytotoxic chemotherapy combinations [abstracts 29]. ASCO Meeting; 2011. p. 3591
   Google Scholar
• Blanke CD, Rankin C, Demetri GD, Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008;26:626-32
   PubMed Web of Science ®Google Scholar
• Saltz LB, Clarke S, Diaz-Rubio E, Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013-19
   PubMed Web of Science ®Google Scholar
• Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer, U.S. National Institutes of Health, 2010
   Google Scholar
• Schmidinger M, Bellmunt J. Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treat Rev 2010;36:416-24
   PubMed Web of Science ®Google Scholar
• Hamberg P, Verweij J, Sleijfer S. (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor. Oncologist 2010;15:539-47
   PubMed Web of Science ®Google Scholar
• Kumar R, Knick VB, Rudolph SK, Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007;6:2012-21
   PubMed Web of Science ®Google Scholar
• Chow LQ, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007;25:884-96.
   PubMed Web of Science ®Google Scholar